MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

Home・Aktien・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

24.58 1.61

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.52

Max

24.59

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.3M -68M
Verkäufe	23M 68M
Gewinnspanne	-99.318
Angestellte	298
EBITDA	42M -15M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+62.87% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	413M 2.1B
Vorheriger Eröffnungskurs	22.97
Vorheriger Schlusskurs	24.58

Nachrichtenstimmung

By Acuity

50%

151 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

9.91 / 14.15 Unterstützung & Widerstand

Syndax Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Apr. 2026, 17:26 UTC

Wichtige Nachrichtenereignisse

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. Apr. 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Market Talk Roundup: Latest on U.S. Politics

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. Apr. 2026, 23:44 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:37 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:15 UTC

Market Talk

Wichtige Nachrichtenereignisse

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. Apr. 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Apr. 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. Apr. 2026, 23:01 UTC

Wichtige Nachrichtenereignisse

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. Apr. 2026, 22:58 UTC

Wichtige Nachrichtenereignisse

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. Apr. 2026, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

7. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Apr. 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. Apr. 2026, 19:17 UTC

Wichtige Nachrichtenereignisse

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. Apr. 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. Apr. 2026, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. Apr. 2026, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. Apr. 2026, 18:39 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. Apr. 2026, 18:24 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. Apr. 2026, 16:21 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Syndax Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

62.87% Vorteil

12-Monats-Prognose

Durchschnitt 39.56 USD 62.87%

Hoch 57 USD

Tief 28 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Syndax Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Syndax Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

9.91 / 14.15Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Stimmung

By Acuity

151 / 349 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.